Rapport Therapeutics, Inc. (NASDAQ: RAPP), founded in 2022, headquartered in Boston, California, USA, with 58 full-time employees, is a clinicalBiopharmaceutical Company, focusing on the discovery and development of transforming small molecule drugs for patients with central nervous system ("CNS") diseases.
The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks-https://www.mg21.com/rapp.html
Rapport Therapeutics (RAPP)
Rapport Therapeutics is a biopharmaceutical company at the clinical stage, focusing on the discovery and development of a series of precision small molecule candidate products. The company believes that these candidate products may change the nursing standards of many central nervous system (CNS) diseases.The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks-https://www.mg21.com/rapp.html
The founder of Rapport Therapeutics revealed the detailed operating mechanism of receptors in the brain, enabling the company to map and locate certain neuronal receptor complexes.These receptors are composed of protein assemblies, including receptor associated proteins (RAP), which play a crucial role in regulating the expression and function of receptors.Rapport Therapeutics' groundbreaking discoveries related to RAP function and structure form the basis of the company's RAP technology platform, which can generate accurate small molecule candidate products by using differentiation methods.The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks-https://www.mg21.com/rapp.html
Neuron receptors are complex assemblies of proteins, including the main subunits of receptors and their receptor related proteins ("RAP"), which play a crucial role in regulating the expression and function of receptors.The founders of the company made groundbreaking discoveries related to RAP functions, which formed the basis of their RAP technology platform.Rapport's profound expertise in RAP biology provides an opportunity for the company to study previously unreachable targets and develop CNS drugs targeting receptor variants and neuroanatomical regions related to certain diseases.The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks-https://www.mg21.com/rapp.html
Most neuroscience drugs lack specificity, which means that they bind to target receptors throughout the brain and often lead to intolerable side effects.With the company's deep expertise in RAP biology, Rapport Therapeutics can develop CNS drugs for receptor variants and brain regions related to certain diseases.The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks-https://www.mg21.com/rapp.html
RAP-219, the leading candidate product of Rapport Therapeutics, is the most advanced candidate product of the company and is a negative allosteric regulator ("NAM") of AMPA receptor ("AMPAR").RAP-219 aims to achieve neuroanatomical specificity by selectively targeting the RAP named TARPg8, which is related to AMPAR, a clinically proven epilepsy target neuron.Rapport has completed the first phase of the test to evaluate the safety and tolerance of RAP-219 in healthy adults, and plans to launch the second phase of the concept validation test for adult patients with drug resistant focal epilepsy in the second or third quarter of 2024. It is expected that the main results will be published in the middle of 2025.The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks-https://www.mg21.com/rapp.html
Rapport Therapeutics product line
Rapport Therapeutics (RAPP) financing encyclopedia
In March 2023, Rapport Therapeutics completed the round A financing of 100 million US dollars led by Third Rock Ventures,ARCH Venture PartnersandJohnson & JohnsonInnovation – JJDC follow investment.The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks-https://www.mg21.com/rapp.html
In August 2023, Rapport Therapeutics completed the round B financing of 150 million US dollars led by Cormorant Asset Management,ARCH Venture Partners、Fidelity、T. Rowe Price、Sofinnova Investments、Perceptive AdvisorsWait for the follow-up.The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks-https://www.mg21.com/rapp.html
Rapport Therapeutics (RAPP) US equity investment
Rapport Therapeutics submitted to the SEC on Friday, May 17, 2024IPOIt is proposed to raise up to US $100 million through IPO.Rapport plans to be listed on NASDAQ with the stock code of RAPP.Goldman Sachs、Jefferies、TDCowenandStifelIs the joint bookrunner of the transaction.Pricing terms are not disclosed.The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks-https://www.mg21.com/rapp.html
In May 2024, by opening an account at American Stock House and merging 10000 Hong Kong dollars (HKD) into Long Bridge, you can get a lifetime free commission of [Hong Kong shares+American shares], and can also get up to 1100 Hong Kong dollars of stock certificates+an additional 88 yuanJD.COMCard (exclusive)+RMB 100 rebate (exclusive).Exclusive to American Stock House customers.Click to view details!
The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks-https://www.mg21.com/rapp.html
two hundred and forty-nine million three hundred and forty-two thousand five hundred and nineteen
WeChat official account: Encyclopedia of US and Hong Kong stocks
WeChat search: mggbkqs
mggbkqs
This article is written byOriginated by American Stock HousePublished on May 18, 2024 at 11:06:47
Original articles of American Stock House,Unauthorized reproduction is strictly prohibited。This article and all articles on this website are intended for information dissemination and sharing, and do not constitute an invitation, solicitation, suggestion, opinion or any guarantee for any securities, financial products or instruments. American Stock House does not endorse any companies, securities firms or financial products.There are risks in investment. Customers should weigh the risks they can bear and make investment judgments independently. If you have any questions, please consult independent professionals.Disclaimer
The ionic receptor of glutamate (iGluR) is a ligand gated ion channel activated by the neurotransmitter glutamate.A subtype of iGluR, AMPAR (α - amino-3-hydroxy-5-methyl-4-isoxazolpropionic acid receptor), affects the overall activity of neural networks.Although many FDA approved drugs can block the glutamate signaling pathway, these drugs are usually accompanied by side effects such as sedation, ataxia, cognitive impairment and neuropsychiatric symptoms.These adverse reactions may be exacerbated by the extensive interaction of these drugs with glutamate receptors throughout the brain.
RAP-219 is a small molecule drug in clinical stage, designed to achieve neuroanatomical specificity by selectively targeting TARP γ 8, a RAP related to neuronal AMPAR.AMPARs are widely distributed in the central nervous system, while TARP γ 8 is only expressed in specific regions - the most abundant region is the hippocampus (usually associated with focal epilepsy), but also in the amygdala and cortex.Because of this restricted expression of TARP γ 8, Rapport Therapeutics believes that RAP-219 has the potential to provide differentiated clinical features, including improved activity and tolerance, and higher treatment index, which may provide more patients with continuous treatment benefits without unbearable side effects.
In addition to evaluating the efficacy of RAP-219 in patients with epilepsy, Rapport Therapeutics is also evaluating the potential of this compound to provide therapeutic benefits in peripheral neuropathic pain and bipolar affective disorder.TARP γ 8 is expressed in pain related central nervous system regions, including anterior cingulate cortex and spinal dorsal horn.In third-party pain models, TARP γ 8 inhibition shows preclinical activity and improves pain behavior in animal models of acute, inflammatory and neuropathic pain.Similarly, in the neuroimaging studies of patients with bipolar affective disorder, it is usually shown that the hippocampus of the brain region expressing TARP γ 8 shows abnormal activation and hyperactivity, as well as high response to emotional stimulation, attention activities and memory tasks.In addition, several antiepileptic drugs have shown clinical benefits in epilepsy and bipolar disorder.
nAChR Programs
Rapport Therapeutics has two advanced discovery phase nicotine acetylcholine receptor (nAChR) projects, which are derived from the company's RAP technology platform.The first discovery phase nAChR project of Rapport Therapeutics includes α 6 nAChRs regulators. The company is developing these drugs for the treatment of chronic pain.Rapport's second discovery phase nAChR project includes α 9 α 10 nAChRs regulators. The company is developing these drugs for the treatment of hearing impairment.Rapport Therapeutics continues to use its RAP technology platform to find more candidate drugs.
